The outcome of our study suggests that the loss of LKB1 expression in HER2 positive breast cancer may serve as a marker for hyperactivation of mTOR, warranting further investigation into combinatorial therapeutics that target LKB1-AMPK-mTOR and glycolytic pathways. The gene discussed is ERBB2; the disease is breast carcinoma.